Neutrophil elastase — Drug Target

All drugs that target Neutrophil elastase — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Protease inhibitor / Enzyme replacement therapy · Protease inhibitor; protein replacement therapy · Protease inhibitor / Protein replacement therapy · Neutrophil elastase inhibitor

Marketed (2)

• alpha-1-Proteinase Inhibitor · Institute for Human Genetics and Biochemistry · Protease inhibitor / Enzyme replacement therapy · Pulmonology / Genetic disease
  Alpha-1-proteinase inhibitor (AAT) replaces or augments deficient alpha-1 antitrypsin to prevent elastin degradation in the lungs and other tissues.
• Alpha 1-Antitrypsin · University of Minnesota · Protease inhibitor; protein replacement therapy · Pulmonology; Genetic/Metabolic Disorders
  Alpha 1-antitrypsin is a protease inhibitor that replaces deficient or dysfunctional alpha 1-antitrypsin protein to prevent neutrophil elastase-mediated tissue destruction in the lungs.

Phase 3 pipeline (1)

• Alpha-1 antitrypsin (AAT) · CSL Behring · Protease inhibitor / Protein replacement therapy · Pulmonology / Genetic / Rare Disease
  Alpha-1 antitrypsin (AAT) is a protease inhibitor that replaces deficient endogenous AAT to prevent neutrophil elastase-mediated tissue destruction in the lungs and other organs.

Phase 2 pipeline (1)

• Alvelestat oral tablet - dose 1 · Mereo BioPharma · Neutrophil elastase inhibitor · Respiratory
  Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue.